Liprolog Junior Kwikpen

Insulin lispro, the active ingredient in Liprolog Junior Kwikpen, is a rapid‑acting insulin analog presented as a pre‑filled pen for subcutaneous use. It is designed to provide fast onset of action to control post‑prandial glucose spikes and is used in the management of diabetes mellitus in both type 1 and type 2 patients.

GNH USA supplies Liprolog Junior Kwikpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin lispro is a rapid‑acting insulin analog used to manage blood glucose in diabetes mellitus.

- Type 1 diabetes mellitus: provides mealtime insulin to achieve post‑prandial glucose control. - Type 2 diabetes mellitus: improves post‑prandial glycaemic control when combined with oral agents or basal insulin. - Pediatric diabetes (children and adolescents): delivers rapid mealtime insulin suitable for younger patients.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections. - Weight gain: modest increase associated with improved glycaemic control. - Nausea: occasional gastrointestinal discomfort. - Headache: mild to moderate tension-type headaches.

Serious or Rare Side Effects: - Severe hypoglycaemia: can lead to loss of consciousness or seizures. - Allergic reactions: rash, urticaria, or anaphylaxis in rare cases. - Insulin antibodies: formation of antibodies that may alter insulin action. - Hypokalemia: low potassium levels, particularly with high insulin doses. - Diabetic ketoacidosis: may occur if insulin therapy is abruptly discontinued.

Insulin lispro requires careful monitoring and individualized dosing.

- Hypoglycaemia risk: monitor blood glucose frequently, especially when initiating therapy. - Dose adjustments: modify dose when changing meal patterns, physical activity, or concurrent medications. - Renal impairment: use with caution; reduced clearance may increase hypoglycaemia risk. - Pregnancy and lactation: consult a healthcare professional before use. - Drug interactions: review all concomitant medicines for potential additive glucose‑lowering effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Beta‑blockers: can mask hypoglycaemia symptoms, making detection difficult. - MAO inhibitors: may potentiate insulin’s glucose‑lowering effect, increasing hypoglycaemia risk.

Moderate Interactions (Monitor Closely): - Sulfonylureas or other insulin secretagogues: additive risk of hypoglycaemia. - Thiazolidinediones: may increase fluid retention when combined with insulin. - Diuretics: can affect electrolyte balance, particularly potassium, influencing insulin action.